Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said ...

Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in ...

Walgreens is offloading more shares in drug distributor Cencora as the struggling pharmacy chain looks to generate cash. The latest sale netted about $300 million for Walgreens, and shrinks the ...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount ...

Cencora (COR) has significantly expanded the number and type of medications available in its sure supply program, a drug shortage mitigation initiative designed to provide health systems with ...

Shares of Cencora, Inc. (NYSE:COR – Get Free Report) reached a new 52-week high on Wednesday after the company announced better than expected quarterly earnings. The company traded as high as $ ...

Hello and welcome everyone to the Cencora Q1 fiscal year 2025 earnings ... and the distributer level to some extent, and just bigger picture, it’s been roughly 10 years since the NWI deal ...

Mauch emphasized the strategic alignment of the RCA acquisition with Cencora’s pharmaceutical-centric strategy. CFO James Cleary noted, "Cencora delivered strong results in the first quarter ...

Healthcare distributor Cencora (NYSE:COR) reported Q4 CY2024 results beating Wall Street’s revenue expectations , with sales up 12.8% year on year to $81.49 billion. Its non-GAAP profit of $3.73 ...

CONSHOHOCKEN, Pa. (AP) — CONSHOHOCKEN, Pa. (AP) — Cencora, Inc. (COR) on Wednesday reported fiscal first-quarter net income of $488.6 million. The Conshohocken, Pennsylvania-based company said ...

Cencora's Q1 sales rose 12.8% to $81.5B, surpassing the estimate, driven by GLP-1 drug sales and specialty product growth. Adjusted EPS grew 13.7% to $3.73, topping the consensus. FY25 EPS outlook ...